Special Instructions

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Limitations

The pathogenic mechanism of aPS-PT antibody morbidity is substantially undefined, although under investigation. To date, aPS/PT antibodies are not included among the formal laboratory classification criteria for APS but are suggested as supplemental assays. The clinical significance of PS/PT IgG or IgM antibodies in diseases other than SLE or APS is currently under investigation. When negative PS/PT IgG or IgM titers are found in the presence of clinical indications, a lupus anticoagulant, anticardiolipin, anti-β2 or other additional testing is indicated. Diagnosis cannot be made on the basis of PS/PT IgG or IgM results alone. These results must be interpreted in conjunction with physical findings. Treatment must not be initiated on the basis of a positive PS/PT IgG or IgM titer alone. Supportive clinical indications must also be present. It is to be expected that some samples can be anticardiolipin positive and/or anti-β2 GPI positive yet PS/PT IgG or IgM negative. The anti-β2 GPI test is a specific marker of thrombotic risk. Patients with APS can be PS/PT positive yet lupus anticoagulant, anticardiolipin or anti-β2 negative.

Biomarkers

LOINC Codes

Result Turnaround Time

Related Documents

Stability Requirements